



Supplementary Fig. S11: *Cxcr3* in CD8 T cells mediates the benefit of GC/ICB combination therapy in orthotopic murine 425-ICC model. (A-E) Outcomes of GC+ICB versus GC alone therapy in 425-ICC-bearing *Rag1*^{-/-}/IC57Bl/6 mice which received CD8⁺ T cell transfer from *Cxcr3*^{-/-}/IC57Bl/6 or *Cxcr3*^{+/+}/IC57Bl/6 mice (n=8 mice). Individual tumor growth kinetics (A), changes in body weight (B), lung metastases (C), bloody ascites (D), and pleural effusions (E). GC: gemcitabine plus cisplatin; ICB: anti-PD-1 antibody plus anti-CTLA-4 antibody. *p < 0.05 from Unpaired t test (C).